Management of Treatment-Resistant Depression: Challenges and Strategies
Received 11 October 2019
Accepted for publication 7 January 2020
Published 21 January 2020 Volume 2020:16 Pages 221—234
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Roger Pinder
Daphne Voineskos, 1, 2 Zafiris J Daskalakis, 1, 2 Daniel M Blumberger 1, 2
1Centre for Addiction and Mental Health, Toronto, Ontario, Canada; 2Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
Correspondence: Daniel M Blumberger
Centre for Addiction and Mental Health, 1001 Queen Street West, Unit 4-1, Toronto, Ontario M6J1H4, Canada
Tel +1 416 535-8501
Fax +1 416 583-1358
Email [email protected]
Abstract: Treatment-resistant depression (TRD) is a subset of Major Depressive Disorder which does not respond to traditional and first-line therapeutic options. There are several definitions and staging models of TRD and a consensus for each has not yet been established. However, in common for each model is the inadequate response to at least 2 trials of antidepressant pharmacotherapy. In this review, a comprehensive analysis of existing literature regarding the challenges and management of TRD has been compiled. A PubMed search was performed to assemble meta-analyses, trials and reviews on the topic of TRD. First, we address the confounds in the definitions and staging models of TRD, and subsequently the difficulties inherent in assessing the illness. Pharmacological augmentation strategies including lithium, triiodothyronine and second-generation antipsychotics are reviewed, as is switching of antidepressant class. Somatic therapies, including several modalities of brain stimulation (electroconvulsive therapy, repetitive transcranial magnetic stimulation, magnetic seizure therapy and deep brain stimulation) are detailed, psychotherapeutic strategies and subsequently novel therapeutics including ketamine, psilocybin, anti-inflammatories and new directions are reviewed in this manuscript. Our review of the evidence suggests that further large-scale work is necessary to understand the appropriate treatment pathways for TRD and to prescribe effective therapeutic options for patients suffering from TRD.
Keywords: treatment resistant depression, major depressive disorder, pharmacotherapy, psychotherapy, brain stimulation, novel therapies
Major Depressive Disorder (MDD) and associated mood syndromes are among the most common psychiatric disorders in specialist and general medical practice. These syndromes span life stages and present with varying combinations of symptoms. While depressive symptoms are at times part of normal human behavior, MDD can be debilitating and at its worst, life threatening. MDD can present at any age across the life span, differences in biological vulnerability, age of onset, risk factors, symptomatic presentation and comorbidities are present among people with the same diagnosis. MDD is, therefore, a very heterogeneous disorder, and approximately 30% of people with this illness are resistant to conventional treatments.96
Several large-scale clinical trials have examined response rates to traditional therapeutic approaches for depression. In the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, the cumulative remission rate after 4 trials of antidepressant treatment (within 14 months) was 67%.125 Even after sequential treatments, 10% to 20% of the MDD patients remained significantly symptomatic for 2 years or longer.69,70 In general, it is accepted that although antidepressant medications can be effective in treating MDD, they fail to achieve remission in approximately 1 out of 3 patients.73
Once 2 adequate antidepressant trials have been unsuccessful, the illness is termed treatment-resistant depression (TRD).125 TRD can also be associated with prolonged, costly periods of inpatient treatment.140 Several definitions and criteria have been proposed to identify true TRD, but a consensus has not yet been agreed to. As such, TRD presents its own challenges for therapeutic approaches and effective treatments. A meta-review of PubMed literature was performed, recent meta-analyses and original studies were collated. The review was limited to studies. In this paper, we will attempt to provide a cohesive review of the treatment approaches for TRD, as well as the challenges unique to managing this illness.
Defining Treatment-Resistant Depression
Although many definitions for TRD have been proposed, the general consensus appears to be 2 unsuccessful trials of antidepressant pharmacotherapy (AD). Several “staging” models to classify levels of treatment resistance have been proposed. The initial model proposed by Thase and Rush138 included treatment resistance levels ranging from one failed AD trial to a lack of response to electroconvulsive therapy (ECT). Further staging models have included the Massachusetts General Hospital Staging method117 which carefully documents the optimization of medication doses and number of failed medications. The Souery Operational Criteria for TRD provide a slightly different approach to staging TRD as an illness, by defining TRD as any single failure of an adequate (6–8 week) trial of an AD.133 The Maudsley Staging Method (MSM) assesses treatment resistance in depression in a “multi-dimensional” manner.34 The majority of investigations into TRD utilize the definition of at least 2 suitable trials of AD without adequate response, although even the term “adequate response” may be fraught with contention, as there is not consensus on what constitutes “adequate.” In fact, even the term TRD may not be the ideal term to define a depressive illness that is not responding to therapeutic interventions. The term “difficult-to-treat depression” has been suggested, with the benefit of not introducing any “therapeutic nihilism” to the psychiatrist–patient relationship.103 For consistency in this manuscript, we will use the term TRD. There has been considerable debate regarding what constitutes TRD, and whether medications from more than one class must be trialed prior to meeting criteria for this classification, or that the focus should be regarding homogeneous biological subtypes or endophenotypes.23 However, the argument may be made that lack of achieving remission may be classified as an inadequate response as residual depressive symptoms can significantly contribute to difficulty functioning. Chronically depressed patients have a lower chance of recovery,98 and often suffer from TRD.25,87
Challenges in Assessing TRD
One of the perils of diagnosing TRD is that of “pseudo-resistance”.107 Pseudo-resistance may encompass the profile of patients who unfortunately were prescribed suboptimal doses of AD or had early discontinuation of a medication for any number of reasons, including intolerable side effects, patient non-adherence or under-dosing. Further, comorbidities such as anxiety disorders, personality disorders or substance-use disorders may complicate the clinical picture and can have deleterious effects on treatment response.114,127 When interviewing patients in assessment of TRD, the potential for recall bias when reporting pharmacological trials and response adds a significant layer of difficulty in diagnosing TRD. Prospectively using objective clinical scales such as the Hamilton Depression Rating Scale48 and the Inventory of Depressive Symptomatology124 and retrospectively using treatment history forms such as the Antidepressant Treatment History Form (ATHF)127 can be very helpful in delineating the nature and course of the treatment resistance. Since the ATHF was initially developed, there have been several developments in the treatment of MDD and specifically TRD, some of which will be elaborated upon in the ensuing sections of this paper. As such, the authors of the original ATHF127 developed an updated and revised version, the short form ATHF (ATHF-SF), as well as an instruction manual and scoring checklist, among other documents.128 Importantly, the ATHF-SF focuses on the current episode of depression, as opposed to life-time trials of pharmacological treatments, a more streamlined approach to assessing the level of resistance of the current illness episode. Utilizing a standardized approach to understand the level of treatment resistance in the current episode of depression may provide a useful measure of consistency in assessment of TRD.
Therapeutic Options for TRD
Traditional Pharmacological Approaches
Augmentation or adjunctive therapy includes the addition of a second medication, not usually considered an antidepressant on its own, to a first-line pharmacotherapeutic option. Below, we have focused on the three main augmentation strategies with strong evidence vs placebo augmentation in detail: lithium, T3 and second-generation antipsychotics.148
Lithium is a naturally occurring salt that was first used in psychiatric treatment in the 1960s.146 The best evidence for augmenting antidepressant pharmacotherapy with lithium comes from studies involving tricyclic antidepressants (TCAs).24 Less evidence exists for augmentation of current first-line antidepressant pharmacotherapy (from the selective serotonin reuptake inhibitor class). A study by Baumann et al9 demonstrated benefit to augmenting citalopram with lithium, resulting in a 60% response rate in 24 patients, compared to a 14% response rate in the placebo arm. The STAR*D trial reported a 16% remission in the group of patients taking citalopram augmented by lithium. However, in this large-scale study, lithium levels were kept quite low, which may have contributed to the low-response rate.108 Large-scale guidelines, including from the American Psychiatric Association (APA)3 and the World Federation of Societies of Biological Psychiatry7 strongly recommend lithium as an effective augmentation strategy in MDD. In fact, a meta-analysis more recently compiled compelling data that lithium is just as effective as the more common second-generation antipsychotics prescribed for augmentation.104 Despite this evidence, and the anti-suicidal nature of lithium,22,47 it continues to be under-utilized and under-prescribed.118
Thyroid hormone levels are known to have a significant effect on mood. Triiodothyronine (T3) is usually the form of thyroid hormone prescribed in augmentation of AD pharmacotherapy.5 This is in contrast to the treatment of hypothyroidism, as T3 is the hormone form which may have CNS activity. As with lithium, the initial T3 studies were performed in augmentation of TCA pharmacotherapy.5,119 In the meta-analysis referenced here, the augmentation of TCA with T3 had a number needed to treat of 4.3.5 In the augmentation of SSRIs, open-label studies have shown some promise.2,63,72 However, in the STAR*D trial, no statistically significant superiority over augmentation with lithium was discovered,108 with the T3 augmentation remission rate at 24.7%. Importantly, however, T3 is generally better tolerated than lithium and requires significantly less clinical monitoring.
In contrast to lithium and T3, second-generation antipsychotics (SGAs) have been investigated as adjunctive therapies in combination specifically with current first-line treatment strategies (i.e. SSRIs and SNRIs). As SGAs are relatively recently developed medications, it has been in the interest of pharma companies to investigate whether these medications can be helpful to treat affective illnesses and therefore be approved to encompass a further class of disorders. This has resulted in several large-scale placebo-controlled RCTs. SGAs are known to have some effect on serotonin receptors and therefore may be effective in combination with SSRI/SNRIs in treating TRD. Specifically, quetiapine,8,31 aripiprazole,12,13,88 olanzapine132 and risperidone68,86 have good evidence in the augmentation of ADs for TRD. Quetiapine at a dose of 300mg per day demonstrated up to 48% response and 24.5% remission in combination with SSRIs and has since been approved for adjunctive treatment of MDD by the FDA.8,31 Olanzapine was examined specifically in combination with fluoxetine, with the combination demonstrating 60% response in a sample of 28 patients with TRD.132
Optimizing, Combining and Switching Classes of Antidepressant Pharmacotherapy
Both the CANMAT and NICE guidelines for treating MDD have recommendations for how to best optimize pharmacotherapy when a patient presents with partial or no symptom response to an initial antidepressant trial. For brevity, we direct readers to these two documents.
The majority of patients seeking pharmacotherapy for MDD are initially started on selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors as first-line treatments for MDD. Older classes of antidepressant pharmacotherapy are reserved for trials of medication once SSRI/SNRI options have been exhausted. Importantly, there is little concrete evidence that switching to medication from the same antidepressant class is an effective strategy for MDD.112 However, several studies have reported that changing classes of medication after non-response to the initial class of antidepressant pharmacotherapy significantly increases response rates. Thase et al139 and Peselow et al116 each examined switching from SSRI/SNRI medications to tricyclic antidepressants (TCAs), specifically imipramine, and reported response rates of 44–73% in total. Monoamine Oxidase Inhibitors (MAOIs) include medications such as tranylcypromine, phenelzine and moclobemide. These are inhibitors of MAO-A and B enzymes and are very effective antidepressants. The majority of studies examining efficacy of switching to an MAOI were conducted by switch from a TCA,95,137 and demonstrated response rates of up to 60%. One step of STAR*D compared tranylcypromine to a combination of mirtazapine and venlafaxine in a group of patients who had not responded to three medication trials. Unfortunately, no significant difference was found in response between the two groups, with only 6.9% remission in the tranylcypromine group, which also suffered from poorer tolerance of the MAOI.94
Psychotherapeutic approaches may be undertaken in combination with somatic or pharmacological treatments, or on their own once several other interventions have been attempted. There appears to be a significant comorbidity of personality disorders with MDD, which then leads to diminishing returns with respect to first line pharmacological treatments.105,106,134 As such, psychotherapy may be employed to address a comorbid diagnosis. A recent Cochrane review examined 6 studies of psychological interventions for TRD,59 including dialectical behavioural therapy, cognitive behavioural therapy, interpersonal therapy and intensive short-term dynamic psychotherapy. In combination with usual care, psychotherapy overall contributed to an improvement in depressive symptoms, especially when the psychotherapy employed was cognitive behavioural analysis system of psychotherapy (CBASP), cognitive behavioural therapy, interpersonal therapy or mindfulness-based cognitive therapy.141 Interestingly, cognitive behavioural therapy appeared to have good effects in the “medium” and “long term” ranges (12 and 46 months, respectively) after the acute treatment phase in terms of lower depression scores.
There are multiple modalities of somatic or brain stimulation therapies which have been investigated and applied in the treatment of TRD and are not first line but are turned to once several trials of pharmacotherapy and/or psychosocial therapies have been ineffective.
ECT is the established best therapeutic option for TRD, but its neurophysiological mechanism of action is yet to be elucidated.66,126 ECT is delivered as a series of high frequency electrical pulses to either the non-dominant right hemisphere and vertex (i.e., unilateral ECT) or bitemporally (bilateral ECT). In ECT, repetitive electrical stimulation over the cortex results in an entrainment of pyramidal cell firing with the subsequent generalization of cortical activity and production of a generalized, tonic-clonic seizure, which typically self-terminates within 30–60 s.
In the treatment of TRD, ECT is applied 2–3 times per week and acute courses can range between 6–18 total sessions. A report from the Consortium for Research in ECT (CORE)57 revealed that over half of the subjects showed an improvement within the first week. Other studies have reported that over 50% of patients who have failed to respond to one or more adequate antidepressant medication trials respond to ECT.120 Meta-analyses have shown that ECT is superior to sham ECT, placebo or antidepressant medications.45,111
Unfortunately, ECT has suffered from extensive stigma in the public eye, likely due to the invasive nature of the treatment and largely due to subsequent negative and abusive portrayals in the media91 including in One flew over the Cuckoo’s Nest, where ECT was portrayed as a punishment, delivered to an individual who did not have a psychotic or affective illness as a form of behavioural control. Along with restriction to access due to availability and risk of memory side effects, this stigma has resulted in ECT being administered to an exceptionally small proportion of individuals with MDD. In fact, a recent investigation of American health insurance databases identified that only 0.25% of almost 1 million patients with a mood disorder received ECT.142 This gross underutilization of ECT persists, despite significant progress in reducing the cognitive side effect profile and alterations in the method of ECT, including seizure threshold titration, inclusion of highly tolerable anaesthetic agents and improvements in peri-procedural care. In 2001, however, the American Psychiatric Association published guidelines4 advising that ECT should be used more frequently than just in “last resort” scenarios in severe medication-resistant patients or where the psychiatric condition is “life-threatening.”
ECT remains the most effective option to treat TRD, especially in situations where a patient’s life may be at risk.149,45 ECT was initially thought to be the most effective in what was previously termed “melancholic depression”, but evidence has demonstrated that a depressive episode with catatonic or psychotic symptoms has a greater likelihood of responding to a course of ECT.113
There are several different forms of ECT which have different response rates and side effect profiles in TRD. Bitemporal Standard pulse ECT is the most commonly used form,76 with a response rate of up to 75%. While the response rate for Right Unilateral Ultrabrief ECT is slightly lower, it remains highly effective. A report by the CORE Group57 found that 65% of patients who underwent bilateral ECT 3 times per week achieved remission by the tenth treatment. In the entire sample, 75% of patients achieved remission by the end of the course, reinforcing the impressive efficacy rate of ECT.
Repetitive Transcranial Magnetic Stimulation
rTMS is a relatively recently developed form of brain stimulation targeting TRD, among other psychiatric diagnoses. Focused pulses of an electromagnetic coil are repetitively discharged over the scalp to stimulate cortical neurons and alter neural excitability without a seizure. Stimulation is applied non-invasively, on the scalp and usually targeted over the DLPFC using a handheld magnetic coil. rTMS has been approved as a treatment for TRD by Health Canada (2002), the US FDA (2008), and equivalent agencies in the European Union, Australia and Israel. The efficacy of rTMS has been established in several dozen randomized controlled trials of thousands of patients over the past 20 years and affirmed in several large meta-analyses.
rTMS was initially tested in healthy volunteers, who demonstrated moderate mood improvements44,115 after application over the left DLPFC. Interestingly, in the initial studies applying treatment to patients with MDD, rTMS was applied over the vertex, not the DLPFC. In two patients with MDD, Hoflich et al only found small improvements to mood, although this was likely due to very low frequency of stimulation (0.3Hz) over the vertex and comparatively few number of stimuli.50 Using focal, high-frequency TMS, George and colleagues found strikingly beneficial effects of rTMS to the left prefrontal cortex in four of six patients with TRD;43 in one of these patients, the beneficial effects of rTMS were associated with normalisation of prefrontal hypometabolism, as shown by positron emission tomography.
Conventional High Frequency Left DLPFC rTMS
The first large clinical trials for rTMS in MDD were published in 2007110 and subsequently in 2010.42 This second study produced a 14.1% remission rate in the blinded study and approximately 30% remission rate in the follow-up open-label trial. Importantly, the retention rate was 88% overall in the randomized controlled trial (RCT) and minor adverse effects were no different in the active vs sham arms of the trial. The remission rate was likely low as patients had fewer stimulus trains and fewer days of treatment. In 2014, Berlim et al reported response rates of 29.3% in 1371 TRD patients,149 almost double the 16.8% response rates seen with antidepressant medications beyond the third sequential trial.125 A systematic review and meta-analysis published in the Journal of Clinical Psychiatry relatively recently, reported that rTMS was 5 times more likely to help TRD patients achieve remission than placebo (“sham”) TMS.40 Moreover, rTMS has an adverse effect discontinuation rate of only 4.5% in stark contrast to the 25.1% discontinuation rate for antidepressant medication.21,64
A second approach with rTMS is to apply the stimulus with rTMS coils of different designs, which allow pulses to target areas deeper into the cortex.29 These coil designs may include double-cone coils,81 Hesel-coils (H-coils)123 and halo coils.130 Early research into these alternate coil designs and configurations determined that by increasing the strength and depth of the stimulus in the cortex, there was a reciprocal relationship with focality of the stimulus.28 That is, the potential of the coil to target structures further from the cortical surface is accompanied by a broader area of stimulus. Deep TMS devices were approved by the FDA beginning in 2013 (the H1-coil) in the treatment of depression, based largely on a study by Levkovitz et al.77 In this study of 212 patients with MDD, the remission rate with deep TMS was 32.6%, compared to 14.6% with sham rTMS. Deep TMS has been shown to be relatively well tolerated, especially in late-life populations.65 Thus, deep TMS is emerging as a further therapeutic rTMS option in TRD.
Theta-burst stimulation (TBS) is a recently developed form of rTMS that appears to more closely target and induce cortical plasticity than conventional rTMS by approximating the endogenous theta frequency emitted by the brain.136 Bursts of 3 stimuli are delivered at a frequency of 50Hz, 5 times per second. TBS can be delivered in either an intermittent (2 s of stimuli then 8 s off for a 10-s train) or continuous pattern. Intermittent TBS (iTBS) is delivered in this 10-s train manner for 190 s (just over 3 mins), consisting of a total of 600 pulses. Several small trials initially indicated that iTBS had the potential to be effective in TRD.19,53,78 These studies prompted a large-scale non-inferiority RCT directly comparing iTBS with conventional 10Hz rTMS.14 In this trial, 414 patients were randomized to either 10Hz rTMS or iTBS and the efficacy of iTBS was found to be noninferior to conventional rTMS. Importantly, tolerability was high in both arms and pain/discomfort scores were similar in each treatment arm. This trial, the largest brain stimulation trial to date, prompted the FDA to approve iTBS as a novel treatment for TRD.
Accelerated rTMS Protocols
As daily rTMS is quite well tolerated but requires several days to weeks of treatment to induce symptom response, newer protocols of multiple treatment sessions per day have been proposed, especially in TRD patients who require urgent response, such as those with acute and severe suicidal ideation. Accelerated treatment schedules have been proposed for both conventional rTMS and TBS treatment paradigms.
Neurophysiological evidence supporting these proposals demonstrates higher levels of neuroplasticity and cortical excitability with multiple rTMS sessions in one day.85 The question of a dose–response relationship has also been posed.41 Several open-label trials of differing accelerated rTMS schedules have been conducted and all found improved remission and response rates, when compared to once daily rTMS6,51,93 including response rates of up to 56%.93 More recently, Fitzgerald et al36 directly compared accelerated rTMS to standard rTMS in a randomized control trial of 115 patients and found no discernible difference in either response or remission rates between the two groups. In this study, patients in the accelerated treatment arm received 3 treatments per day over 3 days in the first week, 3 treatments per day over 2 days in the second week and a single day of 3 treatments in the final, third week, which was compared to daily treatment (5 days per week) for 4 weeks in the standard rTMS arm. There were, however, higher rates of treatment discomfort in the accelerated arm, and this contributed to slightly higher rates of treatment discontinuation in this arm. Most recently, Williams et al143 examined the effects of multiple iTBS treatments per day in a small sample of patients who did not previously respond to a full course of rTMS and an acute course of ECT. Specifically, patients received 10 sessions of iTBS each day for 5 days, a total of 90,000 pulses. Interestingly, the treatment was well tolerated and 4 out of the 6 patients achieved remission at the final session. This intensive study makes an excellent case for ultra-accelerated rTMS in severely treatment refractory patients who would greatly benefit from rapid response to treatment.
As there are several forms of rTMS and numerous approaches attempting to maximize response, it can be challenging to keep track of the best rTMS approach for patients with TRD. Brunoni et al15 examined data regarding the bulk of the existing rTMS therapies available with respect to efficacy and tolerability with the goal of establishing a treatment hierarchy. This novel analysis of 81 rTMS studies examined 8 different rTMS approaches and compared them with sham rTMS. All rTMS interventions were well tolerated, in a similar manner to sham. High frequency, low frequency, bilateral rTMS and TBS were all found to be superior to sham stimulation in terms of response. The analysis suffered from small sample sizes of several investigatory trials and called for new, large-scale, high quality randomized controlled trials to further categorize rTMS paradigms by efficacy. The evidence, therefore, reinforces that rTMS is an effective and well-tolerated therapeutic option for TRD, but more evidence is needed to create a clear hierarchy of rTMS approaches.
Magnetic Seizure Therapy
In magnetic seizure therapy (MST), a powerful repetitively discharged magnet induces focal synchronous activity in the targeted cortical region which then spreads, resulting in a generalized seizure in a similar procedure to ECT.56 It is focally discharged over the prefrontal cortex and evidence shows significantly fewer cognitive side effects with MST. As the magnetic field passes freely through the scalp and skull to discharge cortical neurons, there is no shunting of energy toward subcortical structures,80 thus sparing the memory centres of the brain. As with ECT, several treatments are necessary to result in significant mood symptom improvement. Few clinical trials have yet to be reported regarding the efficacy of MST when compared to other therapeutic options for TRD, but those published consistently demonstrate a clear antidepressant effect with fewer cognitive or memory side effects. A study by Kayser et al67 reported a 69% response rate in 26 patients with TRD, comparable to ECT response rates. Comparably, an earlier pilot study of 13 patients37 reported a response rate of 38% and remission rate of 15%. It should be noted that these studies utilized lower powered MST devices and newer devices have been developed with higher power capacity, comparable to high-dose ECT. The majority of these early studies of MST applied stimulation to the vertex of the skull. A recent paper by Daskalakis et al27 reported an open-label trial applying MST to the prefrontal cortex, with 3 different study arms – each arm applied a different MST frequency, ranging from 25–100Hz. This larger scale trial analysed outcomes for 86 patients with moderately resistant TRD, as assessed by the ATHF. The high-frequency MST resulted in the highest remission rates in patients who underwent at least 8 treatments (33.3%), although this jumped significantly in patients who completed the full MST treatment protocol (to 60%). Cognitive scores remained unaffected, aside from autobiographical memory scores, which would be expected to decrease over time.92 The results of this open-label trial27 appear promising and comparable to ECT, opening the door for further careful direct comparison with ECT and possibly a new favourable brain stimulation option for TRD.
Deep Brain Stimulation
In DBS, a permanent neurosurgical implant is placed in the brain, with a specific target to activate or silence. The implant is connected to a pulse generator in the chest wall that is externally controlled to repetitively stimulate the target area.83 Several regions have been investigated as targets in TRD, namely the nucleus accumbens, ventral capsule and striatum, and the subgenual cingulate cortex (SCC). In small studies, each area has demonstrated promise, and the single high dose study targeting the SCC reported a 92% response rate at 2 years post-implantation in a TRD sample.52 Earlier studies of DBS applied to the SCC report variable response rates over several months that appear to improve over time, ranging from 29% to 75%.74,82,90
Vagus Nerve Stimulation
Vagus nerve stimulation (VNS) is proposed to modulate brain activity via stimulation of the tenth cranial nerve, the vagus nerve. It is believed that the stimulation of this cranial nerve alters various networks of the brain in order to treat psychiatric disease. All VNS systems have required surgical implantation until recently, with the development of transcutaneal systems, which are not yet FDA approved for TRD20,54 The implanted VNS system consists a pulse generator, inserted underneath the skin of the chest. This is then connected to an electrode attached to the left vagus nerve in the neck; together this system delivers pulsed electrical signals to the vagus nerve. A separate device programs the pulse generator stimulation parameters and the implanted device can be temporarily deactivated by holding a magnet over the pulse generator. The FDA approved VNS as an adjunctive long-term therapy for TRD, specifically in patients who have not responded to 4 or more different medications.17 Interestingly, there appears to be a bimodal distribution with respect to the timing of response. A portion of VNS patients respond “acutely,” whereas for others, the main effects appear to emerge after approximately 3 months of treatment.17
In summary, there are several modalities of brain stimulation which have proven effective in TRD. A large meta-analysis of non-surgical brain stimulation in TRD reported on studies of different electrode placements in ECT, several types of rTMS and transcranial direct current stimulation (tDCS).100 Over 6000 patients underwent one of these brain stimulation treatments, despite many trials being of small sample size. As expected, evidence lent itself to ECT, high frequency left and low-frequency right rTMS, with less evidence for the more recently developed forms of brain stimulation. As with the majority of studies in brain stimulation, the bulk of evidence supporting the efficacy of these treatments was assessed by depression scores at the end of the acute course of treatment, with few strategies reported to describe continuation treatment or prevention of relapse. Overall, ECT has the best evidence in the literature to enter a maintenance or continuation phase of therapy, with 84% of individuals who have remitted with ECT relapsing within 6 months if no further treatment (ECT or pharmacotherapy) ensued.129 In the PRIDE Study,71 patients were randomized to a pharmacotherapeutic arm or a combination of continuation ECT with pharmacotherapy, with relapse rates of 20.3% and 13.1%, respectively at the 6-month mark. There is some emerging evidence for a maintenance course of rTMS after effective acute treatment, although this has largely been limited to open-label studies.10,35,109 Large scale, clear data on how best to prevent relapse with rTMS is urgently needed in the field.
Ketamine is a widely investigated N-methyl-D-aspartate (NDMA) antagonist as a potential therapeutic option for TRD and is considered a rapid acting antidepressant (RAADs). More recent evidence purports that ketamine’s antidepressant effects are at least in part due to action on α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors downstream from the initial NMDAR effects.147 Although initially investigated as a psychomimetic substance,75 the antidepressant effect of ketamine was quickly recognized after a low dose intravenous infusion.11 Interestingly, the antidepressant effects were not thought to be due to intoxication but were noted around 3 hrs after the IV infusion had been discontinued and appeared to continue over several days. This rapid response was reinforced by several randomized blinded and open-label studies and included a significant reduction in suicidal ideation in TRD patients.1,58,89,99 On average, the effects of ketamine appear to come on rapidly and last approximately 5–7 days145 with a preferential treatment effect in individuals with comorbid anxiety or an “anxious depression”.60,61 More recently, an intranasal form of esketamine (a ketamine enantiomer) has been developed, which has shown good effect with continued treatment in combination with an oral antidepressant26 and has now been approved by the FDA for restricted use in TRD.
Psilocybin is the psychedelic compound isolated from hallucinogenic mushrooms. It is metabolized by the body into psilocin, which is a partial serotonin receptor agonist. The majority of research into this compound has been limited to small, open label or pilot trials of patients with TRD. In a group of 12 patients with TRD, a feasibility study of high-dose psilocybin demonstrated response rates of 58% up to 3 months after 2 doses of psilocybin, an initial low dose to assess safety and a subsequent high dose (25mg) one week later, despite the psychedelic effects lasting approximately 6 hrs.16 In this study the substance was relatively well tolerated, although transient anxiety was frequently experienced, as was mild tachycardia.
Inflammation is increasingly thought to play a role in TRD, as elevated C-reactive protein and cytokines appear to be elevated in patients with MDD and specifically TRD.18,55,135 Cyclooxygenase-2 inhibitors (COX-2 inhibitors) were initially the focus of anti-inflammatory research in TRD and were investigated as augmentation options for traditional antidepressant pharmacotherapy.32,101 COX-2 inhibitors are known to block prostaglandin production, which appears to be elevated in blood samples of some patients with TRD.79 More recently, a tumour necrosis factor (TNF) antagonist, infliximab, has been investigated specifically in TRD patients with elevated plasma CRP levels, compared to TRD patients without elevated peripheral inflammatory markers.121 The depressive symptoms of patients with elevated CRP levels preferentially responded to infusions of infliximab and their CRP levels dropped post-treatment in a corresponding manner, whereas patients without elevated inflammatory markers did not seem to fall into the responder category. The neurosteroid brexanolone, an intravenous formation of allopregnanolone which acts by enhancing GABAergic inhibition, was FDA approved this year for the treatment of post-partum depression.144 By allosterically enhancing GABAA receptor function, the antidepressant activity of allopregnanolone is attributed to an increase in GABAergic inhibition.97,102 Taken together, these results suggest that anti-inflammatory therapy may have a novel role in treating TRD patients, but largely only in those who demonstrate markers of inflammation.
Novel Therapeutic Compounds and Rapid Acting Antidepressants
As further investigations into MDD and specifically TRD result in the clarification of the disorder’s pathophysiology, the development of novel therapeutic compounds has begun to emerge. These include, but are not limited to, modulators of other central neurotransmitters, such as opioid modulators, cholinergic modulators and γ-aminobutyric acid (GABA) modulators. Of particular interest as medications are RAADs, of which ketamine is the most widely accepted. Novel compounds are now being developed or existing compounds re-examined in this light. In recent years, attention has turned to the endogenous opioid system as one of interest in TRD, particularly when comorbid with anxiety symptoms, as happens relatively frequently, with a negative impact on treatment response.62 Novel compounds targeting the delta opioid receptor have shown promise in small initial drug development trials.122 Existing medications such as buprenorphine have been combined with other compounds to better target the mu and kappa opioid receptors in the hopes of achieving an antidepressant response. These novel combination compounds were deemed tolerable and did not result in opioid withdrawal or tolerance and induced a moderate antidepressant effect,33 showing most promise as an adjunctive therapy. Evidence of hypercholinergic states in MDD39 has also guided research towards the development and examination of anticholinergic compounds, such as the repurposing of scopolamine, an antimuscarinic medication. In a sample of patients with MDD, an initial intravenous infusion of scopolamine resulted in significantly reduced depression and anxiety symptoms within a few days, when compared to placebo.30 The GABA system has been of particular interest in the field of TRD research as it has downstream effects on the serotonergic and noradrenergic systems84 and there is evidence of reduced GABA levels in patients with MDD.49,131 A recently developed positive allosteric GABAA receptor modulator, SAGE-217, was investigated in a multi-site trial of 89 patients with MDD for its potentially acute antidepressant effects.46 On the 15th day of medication administration, of the 45 patients in the active drug arm, 79% met response criteria (>50% reduction in Hamilton Rating Scale for Depression scores), whereas 41% met response criteria in the placebo arm. These novel therapeutics all show promise in effectively treating TRD and warrant further investigation and comparison to existing efficacious TRD therapies.
There are several challenges which accompany the treatment of TRD, not the least of which is the relatively large proportion of patients with MDD who may be classified as having TRD. While several approaches, both traditional and novel, have been developed as described above, further work is necessary to understand the TRD as an illness to adequately treat TRD and notably, to ensure sustained response or continued remission. Several guidelines outlining the treatment of MDD may help to direct practitioners in a logical, step-wise approach (CANMAT, APA, NICE), however, specific guidelines for TRD have not been widely accepted to our knowledge and is certainly out of the scope of a review such as this. A logical approach would likely include beginning with the least invasive and intensive interventions which have the most evidence for efficacy in TRD. Particular promise may be emerging with the newer acute treatments that have recently been approved by the FDA to specifically treat TRD (iTBS and intranasal esketamine). However, large multi-centre trials are still necessary to examine the overarching patterns of TRD illness and treatment response as a whole. Moreover, despite several guidelines touching on recommendations for maintaining response or remission from MDD with effective treatment, aside from continuation strategies with ECT, there is little known about maintaining remission from TRD. In a recent editorial in JAMA Psychiatry, Dr. M. Freeman addresses this specific topic, with recommendations to individualize maintenance interventions.38 That is, the importance of continuing with the treatment that helped the patient reach remission from the most recent depressive episode. With further understanding of the pathophysiology of TRD, patterns of response and how these differ from MDD, we, as treating physicians, may be able to save patients the time, frustration and hopelessness that accompanies numerous failed treatment trials.
Dr. Zafiris J Daskalakis reports grants from Magventure Inc. and grants from Brainsway Inc., during the conduct of the study. The authors report no other conflicts of interest in this work.
1. Aan Het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67(2):139–145. doi:10.1016/j.biopsych.2009.08.038
2. Abraham G, Milev R, Stuart Lawson J. T3 augmentation of SSRI resistant depression. J Affect Disord. 2006;91(2–3):211–215. doi:10.1016/j.jad.2006.01.013
3. APA. Practice guideline for the treatment of patients with major depressive disorder. Available from: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf.
4. APA Committee on Electroconvulsive Therapy. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training and Privileging: A Task Force Report of the American Psychiatric Association; 2001; APA.
5. Aronson R, Offman HJ, Joffe RT, Naylor CD. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry. 1996;53(9):842–848. doi:10.1001/archpsyc.1996.01830090090013
6. Baeken C, Vanderhasselt MA, Remue J, et al. Intensive HF-rTMS treatment in refractory medication-resistant unipolar depressed patients. J Affect Disord. 2013;151(2):625–631. doi:10.1016/j.jad.2013.07.008
7. Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Moller HJ, D. World Federation of Societies of Biological Psychiatry. Task Force on Unipolar Depressive. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013;14(5):334–385. doi:10.3109/15622975.2013.804195
8. Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009;70(4):540–549. doi:10.4088/JCP.08m04629
9. Baumann P, Nil R, Souche A, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol. 1996;16(4):307–314. doi:10.1097/00004714-199608000-00006
10. Benadhira R, Thomas F, Bouaziz N, et al. A randomized, sham-controlled study of maintenance rTMS for treatment-resistant depression (TRD). Psychiatry Res. 2017;258:226–233. doi:10.1016/j.psychres.2017.08.029
11. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–354. doi:10.1016/S0006-3223(99)00230-9
12. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843–853. doi:10.4088/JCP.v68n0604
13. Berman RM, Thase ME, Trivedi MH, et al. Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. Neuropsychiatr Dis Treat. 2011;7:303–312. doi:10.2147/NDT.S18333
14. Blumberger DM, Vila-Rodriguez F, Thorpe KE, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018;391(10131):1683–1692. doi:10.1016/S0140-6736(18)30295-2
15. Brunoni AR, Chaimani A, Moffa AH, et al. Repetitive transcranial magnetic stimulation for the acute treatment of major depressive episodes: a systematic review with network meta-analysis. JAMA Psychiatry. 2017;74(2):143–152. doi:10.1001/jamapsychiatry.2016.3644
16. Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3(7):619–627. doi:10.1016/S2215-0366(16)30065-7
17. Carreno FR, Frazer A. Vagal nerve stimulation for treatment-resistant depression. Neurotherapeutics. 2017;14(3):716–727. doi:10.1007/s13311-017-0537-8
18. Cattaneo A, Ferrari C, Uher R, et al. Absolute measurements of macrophage migration inhibitory factor and interleukin-1-beta mRNA levels accurately predict treatment response in depressed patients. Int J Neuropsychopharmacol. 2016;19(10):
19. Chistyakov AV, Rubicsek O, Kaplan B, Zaaroor M, Klein E. Safety, tolerability and preliminary evidence for antidepressant efficacy of theta-burst transcranial magnetic stimulation in patients with major depression. Int J Neuropsychopharmacol. 2010;13(3):387–393. doi:10.1017/S1461145710000027
20. Cimpianu CL, Strube W, Falkai P, Palm U, Hasan A. Vagus nerve stimulation in psychiatry: a systematic review of the available evidence. J Neural Transm (Vienna). 2017;124(1):145–158. doi:10.1007/s00702-016-1642-2
21. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746–758. doi:10.1016/S0140-6736(09)60046-5
22. Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346:f3646. doi:10.1136/bmj.f3646
23. Conway CR, George MS, Sackeim HA. Defining treatment-resistant depression-reply. JAMA Psychiatry. 2017;74(7):759. doi:10.1001/jamapsychiatry.2017.0970
24. Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry. 2007;68(6):935–940. doi:10.4088/JCP.v68n0617
25. Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry. 2002;63(11):963–971. doi:10.4088/JCP.v63n1102
26. Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2018;75(2):139–148. doi:10.1001/jamapsychiatry.2017.3739
27. Daskalakis ZJ, Dimitrova J, McClintock SM, et al. Magnetic seizure therapy (MST) for major depressive disorder. Neuropsychopharmacology. 2019;45(2):276–282.
28. Deng ZD, Lisanby SH, Peterchev AV. Electric field depth-focality tradeoff in transcranial magnetic stimulation: simulation comparison of 50 coil designs. Brain Stimul. 2013;6(1):1–13. doi:10.1016/j.brs.2012.02.005
29. Deng ZD, Lisanby SH, Peterchev AV. Coil design considerations for deep transcranial magnetic stimulation. Clin Neurophysiol. 2014;125(6):1202–1212. doi:10.1016/j.clinph.2013.11.038
30. Drevets WC, Furey ML. Replication of scopolamine’s antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry. 2010;67(5):432–438. doi:10.1016/j.biopsych.2009.11.021
31. El-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2010;13(7):917–932. doi:10.1017/S1461145710000015
32. Faridhosseini F, Sadeghi R, Farid L, Pourgholami M. Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials. Hum Psychopharmacol. 2014;29(3):216–223. doi:10.1002/hup.v29.3
33. Fava M, Memisoglu A, Thase ME, et al. Opioid modulation with buprenorphine/samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trial. Am J Psychiatry. 2016;173(5):499–508. doi:10.1176/appi.ajp.2015.15070921
34. Fekadu A, Wooderson S, Donaldson C, et al. A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method. J Clin Psychiatry. 2009;70(2):177–184. doi:10.4088/JCP.08m04309
35. Fitzgerald PB, Grace N, Hoy KE, Bailey M, Daskalakis ZJ. An open label trial of clustered maintenance rTMS for patients with refractory depression. Brain Stimul. 2013;6(3):292–297. doi:10.1016/j.brs.2012.05.003
36. Fitzgerald PB, Hoy KE, Elliot D, Susan McQueen RN, Wambeek LE, Daskalakis ZJ. Accelerated repetitive transcranial magnetic stimulation in the treatment of depression. Neuropsychopharmacology. 2018;43(7):1565–1572. doi:10.1038/s41386-018-0009-9
37. Fitzgerald PB, Hoy KE, Herring SE, Clinton AM, Downey G, Daskalakis ZJ. Pilot study of the clinical and cognitive effects of high-frequency magnetic seizure therapy in major depressive disorder. Depress Anxiety. 2013;30(2):129–136. doi:10.1002/da.22005
38. Freeman MP. Relapse prevention after recovery in patients with persistent major depressive disorder-an active pursuit. JAMA Psychiatry. 2019. doi:10.1001/jamapsychiatry.2019.3637
39. Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry. 2006;63(10):1121–1129. doi:10.1001/archpsyc.63.10.1121
40. Gaynes BN, Lloyd SW, Lux L, et al. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis.”. J Clin Psychiatry. 2014;75(5):477–489. doi:10.4088/JCP.13r08815
41. George MS. Transcranial magnetic stimulation for the treatment of depression. Expert Rev Neurother. 2010;10(11):1761–1772. doi:10.1586/ern.10.95
42. George MS, Lisanby SH, Avery D, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry. 2010;67(5):507–516. doi:10.1001/archgenpsychiatry.2010.46
43. George MS, Wassermann EM, Williams WA, et al. Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. Neuroreport. 1995;6(14):1853–1856. doi:10.1097/00001756-199510020-00008
44. George MS, Wassermann EM, Williams WA, et al. Changes in mood and hormone levels after rapid-rate transcranial magnetic stimulation (rTMS) of the prefrontal cortex. J Neuropsychiatry Clin Neurosci. 1996;8(2):172–180.
45. Group UER. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003;361(9360):799–808.
46. Gunduz-Bruce H, Silber C, Kaul I, et al. Trial of SAGE-217 in patients with major depressive disorder. N Engl J Med. 2019;381(10):903–911. doi:10.1056/NEJMoa1815981
47. Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ. Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry. 2007;68(3):380–383. doi:10.4088/JCP.v68n0304
48. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62. doi:10.1136/jnnp.23.1.56
49. Hasler G, van der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 2007;64(2):193–200. doi:10.1001/archpsyc.64.2.193
50. Hoflich G, Kasper S, Hufnagel A, Ruhrmann S, Moller HJ. Application of transcranial magnetic stimulation in treatment of drug-resistant major depression: a report of two cases. Human Psychopharmacol. 1993;8(5):361–365. doi:10.1002/hup.470080510
51. Holtzheimer PE
52. Holtzheimer PE, Kelley ME, Gross RE, et al. Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression. Arch Gen Psychiatry. 2012;69(2):150–158. doi:10.1001/archgenpsychiatry.2011.1456
53. Holzer M, Padberg F. Intermittent theta burst stimulation (iTBS) ameliorates therapy-resistant depression: a case series. Brain Stimul. 2010;3(3):181–183. doi:10.1016/j.brs.2009.10.004
54. Howland RH. New developments with vagus nerve stimulation therapy. J Psychosoc Nurs Ment Health Serv. 2014;52(3):11–14.
55. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71(2):171–186. doi:10.1097/PSY.0b013e3181907c1b
56. Hoy KE, Fitzgerald PB. Magnetic seizure therapy for treatment-resistant depression. Expert Rev Med Devices. 2011;8(6):723–732. doi:10.1586/erd.11.55
57. Husain MM, Rush AJ, Fink M, et al. Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report. J Clin Psychiatry. 2004;65(4):485–491. doi:10.4088/JCP.v65n0406
58. Ibrahim L, Diazgranados N, Luckenbaugh DA, et al. Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(4):1155–1159. doi:10.1016/j.pnpbp.2011.03.019
59. Ijaz S, Davies P, Williams CJ, Kessler D, Lewis G, Wiles N. Psychological therapies for treatment-resistant depression in adults.”. Cochrane Database Syst Rev. 2018;5:CD010558.
60. Ionescu DF, Luckenbaugh DA, Niciu MJ, et al. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. J Clin Psychiatry. 2014;75(9):e932–e938. doi:10.4088/JCP.14m09049
61. Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Zarate CA
62. Ionescu DF, Niciu MJ, Richards EM, Zarate CA
63. Iosifescu DV, Nierenberg AA, Mischoulon D, et al. An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. J Clin Psychiatry. 2005;66(8):1038–1042. doi:10.4088/JCP.v66n0812
64. Janicak PG, O’Reardon JP, Sampson SM, et al. Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. J Clin Psychiatry. 2008;69(2):222–232. doi:10.4088/JCP.v69n0208
65. Kaster TS, Daskalakis ZJ, Noda Y, et al. Efficacy, tolerability, and cognitive effects of deep transcranial magnetic stimulation for late-life depression: a prospective randomized controlled trial. Neuropsychopharmacology. 2018;43(11):2231–2238. doi:10.1038/s41386-018-0121-x
66. Kato N. Neurophysiological mechanisms of electroconvulsive therapy for depression. Neurosci Res. 2009;64(1):3–11. doi:10.1016/j.neures.2009.01.014
67. Kayser S, Bewernick BH, Matusch A, Hurlemann R, Soehle M, Schlaepfer TE. Magnetic seizure therapy in treatment-resistant depression: clinical, neuropsychological and metabolic effects. Psychol Med. 2015;45(5):1073–1092. doi:10.1017/S0033291714002244
68. Keitner GI, Garlow SJ, Ryan CE, et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res. 2009;43(3):205–214. doi:10.1016/j.jpsychires.2008.05.003
69. Keitner GI, Ryan CE, Solomon DA. Realistic expectations and a disease management model for depressed patients with persistent symptoms. J Clin Psychiatry. 2006;67(9):1412–1421. doi:10.4088/JCP.v67n0912
70. Keller MB, Shapiro RW, Lavori PW, Wolfe N. Recovery in major depressive disorder: analysis with the life table and regression models. Arch Gen Psychiatry. 1982;39(8):905–910. doi:10.1001/archpsyc.1982.04290080025004
71. Kellner CH, Husain MM, Knapp RG, et al. A novel strategy for continuation ECT in geriatric depression: phase 2 of the PRIDE study. Am J Psychiatry. 2016;173(11):1110–1118. doi:10.1176/appi.ajp.2016.16010118
72. Kelly TF, Lieberman DZ. Long term augmentation with T3 in refractory major depression. J Affect Disord. 2009;115(1–2):230–233. doi:10.1016/j.jad.2008.09.022
73. Kennedy SH, Giacobbe P. Treatment resistant depression–advances in somatic therapies. Ann Clin Psychiatry. 2007;19(4):279–287. doi:10.1080/10401230701675222
74. Kennedy SH, Giacobbe P, Rizvi SJ, et al. Deep brain stimulation for treatment-resistant depression: follow-up after 3 to 6 years. Am J Psychiatry. 2011;168(5):502–510. doi:10.1176/appi.ajp.2010.10081187
75. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51(3):199–214. doi:10.1001/archpsyc.1994.03950030035004
76. Leiknes KA, Jarosh-von Schweder L, Hoie B. Contemporary use and practice of electroconvulsive therapy worldwide. Brain Behav. 2012;2(3):283–344. doi:10.1002/brb3.37
77. Levkovitz Y, Isserles M, Padberg F, et al. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. World Psychiatry. 2015;14(1):64–73. doi:10.1002/wps.20199
78. Li CT, Chen MH, Juan CH, et al. Efficacy of prefrontal theta-burst stimulation in refractory depression: a randomized sham-controlled study. Brain. 2014;137(Pt 7):2088–2098. doi:10.1093/brain/awu109
79. Lieb J, Karmali R, Horrobin D. Elevated levels of prostaglandin E2 and thromboxane B2 in depression. Prostaglandins Leukot Med. 1983;10(4):361–367. doi:10.1016/0262-1746(83)90048-3
80. Lisanby SH. Update on magnetic seizure therapy: a novel form of convulsive therapy. J ECT. 2002;18(4):182–188. doi:10.1097/00124509-200212000-00003
81. Lontis ER, Voigt M, Struijk JJ. Focality assessment in transcranial magnetic stimulation with double and cone coils. J Clin Neurophysiol. 2006;23(5):462–471. doi:10.1097/01.wnp.0000229944.63011.a1
82. Lozano AM, Giacobbe P, Hamani C, et al. A multicenter pilot study of subcallosal cingulate area deep brain stimulation for treatment-resistant depression. J Neurosurg. 2012;116(2):315–322. doi:10.3171/2011.10.JNS102122
83. Lozano AM, Mayberg HS, Giacobbe P, Hamani C, Craddock RC, Kennedy SH. Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatry. 2008;64(6):461–467. doi:10.1016/j.biopsych.2008.05.034
84. Luscher B, Shen Q, Sahir N. The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry. 2011;16(4):383–406.
85. Maeda F, Keenan JP, Tormos JM, Topka H, Pascual-Leone A. Modulation of corticospinal excitability by repetitive transcranial magnetic stimulation. Clin Neurophysiol. 2000;111(5):800–805. doi:10.1016/S1388-2457(99)00323-5
86. Mahmoud RA, Pandina GJ, Turkoz I, et al. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med. 2007;147(9):593–602. doi:10.7326/0003-4819-147-9-200711060-00003
87. Malhi GS, Parker GB, Crawford J, Wilhelm K, Mitchell PB. Treatment-resistant depression: resistant to definition? Acta Psychiatr Scand. 2005;112(4):302–309. doi:10.1111/acp.2005.112.issue-4
88. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(2):156–165. doi:10.1097/JCP.0b013e31816774f9
89. Mathew SJ, Murrough JW, Aan Het Rot M, Collins KA, Reich DL, Charney DS. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial.”. Int J Neuropsychopharmacol. 2010;13(1):71–82. doi:10.1017/S1461145709000169
90. Mayberg HS, Lozano AM, Voon V, et al. Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45(5):651–660. doi:10.1016/j.neuron.2005.02.014
91. McDonald A, Walter G. The portrayal of ECT in American movies. J ECT. 2001;17(4):264–274. doi:10.1097/00124509-200112000-00006
92. McElhiney MC. The Autobiographical Memory Interview-Short Form. In: Psychiatry DoB. New York: New York State Psychiatric Institute; 2001.
93. McGirr A, Van den Eynde F, Tovar-Perdomo S, Fleck MP, Berlim MT. Effectiveness and acceptability of accelerated repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant major depressive disorder: an open label trial. J Affect Disord. 2015;173:216–220. doi:10.1016/j.jad.2014.10.068
94. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry. 2006;163(9):1531–1541. doi:10.1176/ajp.2006.163.9.1531
95. McGrath PJ, Stewart JW, Harrison W, Quitkin FM. Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor antidepressant. Psychopharmacol Bull. 1987;23(1):169–172.
96. McLachlan G. Treatment resistant depression: what are the options? BMJ. 2018;363:k5354. doi:10.1136/bmj.k5354
97. Meltzer-Brody S, Colquhoun H, Riesenberg R, et al. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, Phase 3 trials. Lancet. 2018;392(10152):1058–1070. doi:10.1016/S0140-6736(18)31551-4
98. Mueller TI, Leon AC. Recovery, chronicity, and levels of psychopathology in major depression. Psychiatr Clin North Am. 1996;19(1):85–102. doi:10.1016/S0193-953X(05)70275-6
99. Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013;74(4):250–256. doi:10.1016/j.biopsych.2012.06.022
100. Mutz J, Vipulananthan V, Carter B, Hurlemann R, Fu CHY, Young AH. Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis. BMJ. 2019;364:l1079. doi:10.1136/bmj.l1079
101. Na KS, Lee KJ, Lee JS, Cho YS, Jung HY. Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2014;48:79–85. doi:10.1016/j.pnpbp.2013.09.006
102. Naguy A. Brexanolone and postpartum depression: what does it have to do with GABA? Arch Womens Ment Health. 2019;22(6):833–834. doi:10.1007/s00737-019-00986-0
103. Naguy A, Alamiri B, Al Awadhi DS. Treatment-resistant depression: A plea to mull over! Asian J Psychiatr. 2018;36:69–70. doi:10.1016/j.ajp.2018.06.014
104. Nelson JC, Baumann P, Delucchi K, Joffe R, Katona C. A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. J Affect Disord. 2014;168:269–275. doi:10.1016/j.jad.2014.05.053
105. Newton-Howes G, Tyrer P, Johnson T. Personality disorder and the outcome of depression: meta-analysis of published studies. Br J Psychiatry. 2006;188:13–20. doi:10.1192/bjp.188.1.13
106. Newton-Howes G, Tyrer P, Johnson T, et al. Influence of personality on the outcome of treatment in depression: systematic review and meta-analysis. J Pers Disord. 2014;28(4):577–593. doi:10.1521/pedi_2013_27_070
107. Nierenberg AA, Amsterdam JD.Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry. 1990;51(Suppl):39–47.
108. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 2006;163(9):1519–1530. doi:10.1176/ajp.2006.163.9.1519
109. O’Reardon JP, Blumner KH, Peshek AD, Pradilla RR, Pimiento PC. Long-term maintenance therapy for major depressive disorder with rTMS. J Clin Psychiatry. 2005;66(12):1524–1528. doi:10.4088/JCP.v66n1205
110. O’Reardon JP, Solvason HB, Janicak PG, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry. 2007;62(11):1208–1216. doi:10.1016/j.biopsych.2007.01.018
111. Pagnin D, de Queiroz V, Pini S, Cassano GB. Efficacy of ECT in depression: a meta-analytic review. J ECT. 2004;20(1):13–20. doi:10.1097/00124509-200403000-00004
112. Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry. 2008;63(7):699–704. doi:10.1016/j.biopsych.2007.08.010
113. Parker G, Roy K, Hadzi-Pavlovic D, Pedic F. Psychotic (delusional) depression: a meta-analysis of physical treatments. J Affect Disord. 1992;24(1):17–24. doi:10.1016/0165-0327(92)90056-C
114. Parker GB, Malhi GS, Crawford JG, Thase ME. Identifying “paradigm failures” contributing to treatment-resistant depression. J Affect Disord. 2005;87(2–3):185–191. doi:10.1016/j.jad.2005.02.015
115. Pascual-Leone A, Catala MD, Pascual-Leone A. Lateralized effect of rapid-rate transcranial magnetic stimulation of the prefrontal cortex on mood. Neurology. 1996;46(2):499–502. doi:10.1212/WNL.46.2.499
116. Peselow ED, Filippi AM, Goodnick P, Barouche F, Fieve RR. The short- and long-term efficacy of paroxetine HCl: A. Data from a 6-week double-blind parallel design trial vs. imipramine and placebo. Psychopharmacol Bull. 1989;25(2):267–271.
117. Petersen T, Papakostas GI, Posternak MA, et al. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol. 2005;25(4):336–341. doi:10.1097/01.jcp.0000169036.40755.16
118. Post RM. The new news about lithium: an underutilized treatment in the United States. Neuropsychopharmacology. 2018;43(5):1174–1179. doi:10.1038/npp.2017.238
119. Prange AJ
120. Prudic J, Haskett RF, Mulsant B, et al. Resistance to antidepressant medications and short-term clinical response to ECT. Am J Psychiatry. 1996;153(8):985–992.
121. Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70(1):31–41. doi:10.1001/2013.jamapsychiatry.4
122. Richards EM, Mathews DC, Luckenbaugh DA, et al. A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression. Psychopharmacology (Berl). 2016;233(6):1119–1130. doi:10.1007/s00213-015-4195-4
123. Roth Y, Zangen A, Hallett M. A coil design for transcranial magnetic stimulation of deep brain regions. J Clin Neurophysiol. 2002;19(4):361–370. doi:10.1097/00004691-200208000-00008
124. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med. 1996;26(3):477–486. doi:10.1017/S0033291700035558
125. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917. doi:10.1176/ajp.2006.163.11.1905
126. Sackeim HA. Central issues regarding the mechanisms of action of electroconvulsive therapy: directions for future research. Psychopharmacol Bull. 1994;30(3):281–308.
127. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62(Suppl 16):10–17.
128. Sackeim HA, Aaronson ST, Bunker MT, et al. The assessment of resistance to antidepressant treatment: rationale for the Antidepressant Treatment History Form: Short Form (ATHF-SF). J Psychiatr Res. 2019;113:125–136. doi:10.1016/j.jpsychires.2019.03.021
129. Sackeim HA, Haskett RF, Mulsant BH, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA. 2001;285(10):1299–1307. doi:10.1001/jama.285.10.1299
130. Samoudi AM, Tanghe E, Martens L, Joseph W. Deep transcranial magnetic stimulation: improved coil design and assessment of the induced fields using MIDA model. Biomed Res Int. 2018;(2018:7061420.
131. Sanacora G, Gueorguieva R, Epperson CN, et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry. 2004;61(7):705–713. doi:10.1001/archpsyc.61.7.705
132. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001;158(1):131–134. doi:10.1176/appi.ajp.158.1.131
133. Souery D, Amsterdam J, de Montigny C, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 1999;9(1–2):83–91. doi:10.1016/S0924-977X(98)00004-2
134. Souery D, Oswald P, Massat I, et al., D. Group for the Study of Resistant. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry. 2007;68(7):1062–1070. doi:10.4088/JCP.v68n0713
135. Strawbridge R, Arnone D, Danese A, Papadopoulos A, Herane Vives A, Cleare AJ. Inflammation and clinical response to treatment in depression: A meta-analysis. Eur Neuropsychopharmacol. 2015;25(10):1532–1543. doi:10.1016/j.euroneuro.2015.06.007
136. Suppa A, Huang YZ, Funke K, et al. Ten years of theta burst stimulation in humans: established knowledge, unknowns and prospects. Brain Stimul. 2016;9(3):323–335. doi:10.1016/j.brs.2016.01.006
137. Thase ME, Frank E, Mallinger AG, Hamer T, Kupfer DJ. Treatment of imipramine-resistant recurrent depression, III: efficacy of monoamine oxidase inhibitors. J Clin Psychiatry. 1992;53(1):5–11.
138. Thase ME, Rush AJ. Treatment resistant depression. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press Ltd.; 1995:1081–1097.
139. Thase ME, Rush AJ, Howland RH, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry. 2002;59(3):233–239. doi:10.1001/archpsyc.59.3.233
140. Ustun TB, Kessler RC. Global burden of depressive disorders: the issue of duration. Br J Psychiatry. 2002;181:181–183. doi:10.1192/bjp.181.3.181
141. van Bronswijk S, Moopen N, Beijers L, Ruhe HG, Peeters F. Effectiveness of psychotherapy for treatment-resistant depression: a meta-analysis and meta-regression. Psychol Med. 2019;49(3):366–379. doi:10.1017/S003329171800199X
142. Wilkinson ST, Agbese E, Leslie DL, Rosenheck RA. Identifying recipients of electroconvulsive therapy: data from privately insured Americans. Psychiatr Serv. 2018;69(5):542–548. doi:10.1176/appi.ps.201700364
143. Williams NR, Sudheimer KD, Bentzley BS, et al. High-dose spaced theta-burst TMS as a rapid-acting antidepressant in highly refractory depression. Brain. 2018;141(3):e18. doi:10.1093/brain/awx379
144. Wisner KL, Stika CS, Ciolino JD. The first food and drug administration-indicated drug for postpartum depression-brexanolone. JAMA Psychiatry. 2019;76:1001. doi:10.1001/jamapsychiatry.2019.1546
145. Xu Y, Hackett M, Carter G, et al. Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2016;19(4).
146. Zall H, Therman PG, Myers JM. Lithium carbonate: a clinical study. Am J Psychiatry. 1968;125(4):549–555. doi:10.1176/ajp.125.4.549
147. Zanos P, Gould TD. Mechanisms of ketamine action as an antidepressant. Mol Psychiatry. 2018;23(4):801–811. doi:10.1038/mp.2017.255
148. Zhou X, Ravindran AV, Qin B, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry. 2015;76(4):e487–e498. doi:10.4088/JCP.14r09204
149. Berlim MT, van den Eynde F, Tovar-Perdomo S, Daskalakis ZJ. Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials. Psychol Med. 2014;44(2):225–39.
© 2020 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.